The largest database of trusted experimental protocols

Pgl4.75 hrluc cmv plasmid

Manufactured by Promega
Sourced in United States

The PGL4.75 [hRluc/CMV] plasmid is a lab equipment product offered by Promega. It is a vector that contains the humanized Renilla luciferase (hRluc) gene under the control of the cytomegalovirus (CMV) promoter.

Automatically generated - may contain errors

3 protocols using pgl4.75 hrluc cmv plasmid

1

NF-κB Transcriptional Activity Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Luciferase assays were performed to determine the NF-κB activity in response to poly(dA:dT) treatment. The HPV-KER cell line was transfected with the NF-κB reporter construct vector pNF-κB-luc Cis-Reporter Plasmid (Stratagene, La Jolla, CA, USA) and the pGL4.75 [hRluc/CMV] plasmid (Promega, Madison, WI, USA) with the use of the X-tremeGene9 transfection reagent. The treated cells were washed twice with PBS, lysed with passive lysis buffer (Biotium, Hayward, CA, USA) and the luciferase activities in the lysates were measured using the Firefly & Renilla Dual Luciferase Assay Kit (Biotium) and Thermo Luminoskan Ascent (Thermo Scientific, Rockford, IL, USA), according to the manufacturer’s instructions. All samples were measured three times and the luciferase activity derived from the NF-κB-luc plasmid was normalized to the activity of the Renilla luciferase activity from pGL4.75 [hRluc/CMV] plasmid.
+ Open protocol
+ Expand
2

Transfection of CCDC88C in HEK293 cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The HEK293 cell line (Merck, Darmstadt, Germany) was maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Lonza, Basel, Switzerland), 1% L-glutamine (Lonza) and 1% antimycotic–antibiotic solution (Lonza) at 37 °C in a humidified atmosphere with 5% CO2.
For transfection, cells were seeded into 12-well plates at a density of 300,000 cells/mL in full medium. After 48 h, medium was changed to FBS-free medium, and cells were co-transfected with the AP1–LUC cis-reporter plasmid, the pGL4.75 (hRluc/CMV) plasmid (Promega), which was used as internal control, and 1µg pcDNA3.1+/C-(K)DYK vector (GenScript) carrying the WT or mutant CCDC88C cDNA sequences. Transfection was carried out with the Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions. Mock-transfection by transfection reagent and cotransfection of luciferase plasmids with the empty pcDNA3.1(+) plasmid served as control. Twenty-four hours after transfection, cell samples were collected for extraction of proteins, which were subjected to luciferase activity measurement or to TUNEL assay.
+ Open protocol
+ Expand
3

In Vitro Analysis of CYLD Polymorphisms

Check if the same lab product or an alternative is used in the 5 most similar protocols
To clarify the contribution of the identified polymorphisms to modifying CYLD's role in the disease, an in vitro experimental system was designed. The main role of CYLD is the regulation of TNFR-mediated NF-κB activation. To monitor NF-κB activity, HEK293 cells were cotransfected with the pNFκB-luc Cis-Reporter plasmid (StrataGene), the pGL4.75 [hRluc/CMV] plasmid (Promega), which was used as internal control, and different combinations of the pcDNA3.1(+) vector (Invitrogen) carrying the wild type or mutant CYLD, TRAF3 and NBR1 cDNAs fused with tag sequences, which were added for easy detection by western blot. The viability of the HEK293 cells was not affected by the transfection with any combinations of the plasmids as it was assessed by MTT assay (Figure S1) and followed by regular microscopic control. The expression levels of CYLD, TRAF3 and NBR1 proteins were determined by western blot analyses.
Detailed description on the materials and methods are found in Appendix S1.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!